Lotte Biologics公司在锡拉丘兹推出了新的ADC制造设施,标志着美国第一份合同。 Lotte Biologics launches new ADC manufacturing facility in Syracuse, marking first U.S. contract.

韩国生物技术公司Lotte Biologics已经签署了第一份制造合同,为一家设在亚洲的公司进行临床试验生产一个抗体药物联合体(ADC)。 South Korean biotech firm Lotte Biologics has signed its first manufacturing contract to produce an antibody-drug conjugate (ADC) for a clinical trial with an Asia-based firm. 这标志着Lotte Biologics在纽约锡拉丘兹新的ADC设施的启动,该设施符合美国制造标准。 This marks the launch of Lotte Biologics' new ADC facility in Syracuse, New York, which meets U.S. manufacturing standards. 该公司对该设施投资1亿美元,目的是成为生物技术部门的主要供应商,到2030年实现10.5亿美元的销售。 The company has invested $100 million in the facility, aiming to become a leading provider in the biotech sector and achieve $1.05 billion in sales by 2030.